Ainos is engaged in developing biologics for the treatment of human and animal diseases. Co. primarily operates through three divisions: Pharmaceutical, Medical and Consumer. The Pharmaceutical division utilizes Co.'s data library by applying Co.'s knowledge in the use of low-dose oral interferon for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division is focused on developing technology to treat metabolism related diseases such as Type 1 and Type 2 diabetes in Asia, in addition to licensed distribution of surgical wound care products. The Consumer division includes nutraceutical and food supplement products that utilize a liposomal delivery system. The AIMD average annual return since 2021 is shown above.
The Average Annual Return on the AIMD average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AIMD average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AIMD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|